GLAXO WELLCOME ULTIVA ANALGESIC OPIOID RAPID ONSET/OFFSET TIME IN GENERAL ANESTHESIA ACHIEVES EFFECT WITHOUT DELAYING PATIENT RECOVERY -- FDA CMTE.
Glaxo Wellcome's Ultiva (remifentanil) is different from other opioid analgesics because its half-life of three to six minutes allows for a much more rapid onset/offset time, the company said during an April 29 presentation before FDA's Anesthetic & Life Support Advisory Committee, which recommended Ultiva for approval. Glaxo's NDA submission was filed in September 1995.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth